Search Contact Legal Statement
Index Sitemap link to Roche Diagnostics Global
About us Health Information News Related links Contact us Careers
UK Press Releases

Global Press Releases

Archived Press Releases
border=FDA approves most comprehensive test for the simultaneous screening of donated blood for HIV, Hepatitis B & Hepatitis C
The United States Food & Drug Administration (FDA) today approved a new nucleic acid test from Roche to screen donated blood for HIV-1 Group M RNA, hepatitis C RNA and hepatitis B DNA in a single, automated assay.
border=MabThera inhibits the destruction of joints in patients with early rheumatoid arthritis
Roche announced today that MabThera (rituximab) can significantly inhibit structural damage to joints in patients with early rheumatoid arthritis (RA) who have not been treated with methotrexate (MTX), the current standard of care for RA treatment.
border=Herceptin given prior to surgery improves the chance of survival without relapse for women with HER2-positive breast cancer
About 70% of women with locally advanced HER2-positive breast cancer were free of their disease three years after initiation of therapy when treated with Herceptin plus chemotherapy before surgery, compared to only around 50% of patients receiving pre-operative chemotherapy alone.
border=New data show that Herceptin, Xeloda and Avastin help patients with early and advanced breast cancer live longer or remain disease free for longer
New data being presented at the CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) show that Herceptin (trastuzumab), Avastin (bevacizumab) and oral Xeloda (capecitabine) continue to offer new and better treatment options for breast cancer patients allowing women to live longer or disease free for longer if the medicines are given before and after surgery as well as in advanced stages of disease.
border=Jonathan Knowles to retire from Roche at the end of 2009
Prof. Jonathan Knowles, Head of Group Research and member of the Corporate Executive Committee of Roche, will retire from Roche at the end of 2009.
border=New data from largest-ever clinical trials in CLL show MabThera enables leukaemia patients to live longer without their disease progressing
Significant new data from two pivotal phase III studies, to be presented at the 50th Annual Meeting of the American Society of Hematology in San Francisco this week, show that patients with chronic lymphocytic leukaemia (CLL) treated with MabThera (rituximab) in combination with chemotherapy live considerably longer without their disease progressing, compared to patients treated with chemotherapy alone.
border=European Commission approval of new indication for Roche's Pegasys offers hepatitis C patients a second chance for a cure
Roche announced today that the European Commission has approved Pegasys (peginterferon alfa-2a [40 KD]) plus Copegus (ribavirin) for the retreatment of hepatitis C patients who were not successfully treated with an initial course of interferon alpha (pegylated or non-pegylated), either alone or in combination with ribavirin.
border=Roche and FDA Agree on Pathway Towards U.S. Approval of Actemra (tocilizumab)
Roche today announced that the U.S. Food and Drug Administration (FDA) has provided further guidance on the requirements for the Biologics License Application (BLA) for Actemra (tocilizumab), the first interleukin-6 (IL-6) receptor-inhibiting monoclonal antibody studied for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA).
border=6th Roche Children's Walk: some 14’000 employees from 100 sites worldwide walk today to support children in need
On 1st December for the sixth consecutive year, Roche will be holding a sponsored worldwide walk to raise money to help orphans and children in need. With their participation, the Roche employees demonstrate their solidarity and ongoing commitment to help support children in Malawi and childrens’ organisations in their own countries. All funds raised by employees are matched by Roche.
border=Roche signs definitive agreement to acquire Memory Pharmaceuticals
Roche and Memory Pharmaceuticals today announced that the two companies have signed a definitive merger agreement for Roche to fully acquire Memory in an all-cash transaction at a price of approximately USD 50 million.
top
See our Legal Statement
This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any valid legal process, regulation, registration or usage in the country of your origin.